Engflag

Salurin

Quick links to important sections

Salurin

Salurin_EN

Method of action: Chlororetic, Diuretic, Hypotensive, Natriuretic

Treatment option: Ascites, Hypertensive Crisis, Nephrotic Syndrome, Heart Failure

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salurin

Property Description
Active Ingredient Furosemide
Form Tablet, Solution for Injection
Pharmacological Class Diuretic (High-Ceiling Class)
Common Use Alleviation of Edema (Fluid Retention)
Origin Synthetic Compound (Sulfonamide Derivative)

Salurin: Defining the High-Ceiling Diuretic

Salurin is a synthetic prescription medication whose active ingredient is the compound Furosemide, primarily defined as a diuretic designed to manage fluid balance in the body. It belongs to the specific pharmacological classification of high-ceiling diuretics, which are also known as loop diuretics, reflecting its unique site and powerful mechanism of action within the kidney. Furosemide is globally classified as an essential medicine. Its status in this category reflects the drug's established efficacy and general safety profile as a necessary medicine in basic healthcare systems.

As a single-ingredient product, Salurin relies solely on Furosemide, which is chemically categorized as a sulfonamide derivative. This medicine is made available in several dosage forms, including a solid tablet for oral consumption and a sterile solution for injection for parenteral administration when rapid effects are clinically necessary. The potency of this class is clinically recognized for its ability to produce significant water loss even in cases where other diuretics might fail.

Understanding Salurin’s Primary Action and Purpose

The primary action of Salurin is to cause a significant and rapid increase in the removal of excess salt and water from the body through the kidneys, which is its central therapeutic purpose. This is achieved by stimulating natriuresis, the powerful physiological action that results in the enhanced excretion of sodium and chloride. Loop diuretics are clinically characterized as the most effective class for initiating rapid, profound diuresis.

The general benefit derived from this action is the essential alleviation of conditions characterized by volume overload or the abnormal accumulation of fluid in body tissues, a condition known as edema. By promoting the rapid expulsion of this excess volume, Salurin contributes to relieving associated physical symptoms and helps manage fluid pressure within the circulatory system.

Regulatory References

  1. Furosemide Vitabalans - referral | European Medicines Agency (EMA)
  2. Loop Diuretics - StatPearls - NCBI Bookshelf (NIH)

What side effects are possible with Salurin?

Possible Side Effects and Safety Information

Salurin, containing the high-ceiling diuretic Furosemide, has an established safety profile primarily characterized by the consequences of its potent action on fluid and electrolyte balance, as documented in official regulatory sources. The adverse reactions are classified by frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most frequent reactions are directly related to the medicine's primary function, leading to changes in volume and electrolyte status.

  • Very Common (ge 1/10): Dehydration, hypovolemia, hyponatremia (low sodium), hypokalemia (low potassium), hypochloremic metabolic alkalosis, and hypotension (low blood pressure).
  • Uncommon (ge 1/1,000 to < 1/100): Thrombocytopenia (low platelets), deafness (sometimes irreversible), visual disturbance, and nausea.
  • Rare (ge 1/10,000 to < 1/1,000): Tinnitus (ringing in the ears), acute pancreatitis, anaphylactic reactions, and blood disorders such as leukopenia.

Serious Adverse Reactions and Population-Specific Safety

Official labeling notes serious risks and safety considerations for specific groups:

  • Serious Adverse Reactions: The risk of Circulatory Collapse and Thrombosis/Embolism exists due to severe volume depletion. Ototoxicity (hearing loss) and the potential for Hepatic Encephalopathy in patients with pre-existing liver impairment are also documented. Rare but severe skin reactions include Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Population Considerations: Older adults are particularly susceptible to excessive diuresis and dehydration. The risk of nephrocalcinosis is noted for premature infants during long-term use. A potential for cross-hypersensitivity reactions is noted for patients with a known sulfonamide allergy, consistent with the drug's chemical class.

Safety Restrictions and Contextual Notes

The medicine is officially contraindicated in patients with anuria (inability to produce urine). Additionally, the risk of ototoxicity is specifically stated to be higher when Furosemide is given via rapid intravenous injection and in combination with other ototoxic medicines.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Salurin (Furosemide) primarily manifests as an exaggeration of its potent diuretic effect, leading to severe volume and electrolyte depletion. These consequences define when emergency medical attention must be sought, as specified in regulatory labeling.

Documented Overdose Presentations and Outcomes

Classification Official Regulatory Statement
Core Manifestations Dehydration, Hypovolemia (reduced blood volume), Hypotension, and laboratory-confirmed Electrolyte Imbalance (Hypokalemia, Hyponatremia).
Severe Outcomes Risk of Circulatory Collapse and the potential for Vascular Thrombosis and Embolism. Irreversible Hearing Impairment (Ototoxicity) and Tinnitus are associated with doses substantially higher than recommended.
Specific Risks Elderly patients face increased risk of circulatory collapse. Patients with pre-existing hepatic disease risk precipitating Hepatic Encephalopathy and Coma.

Required Emergency Actions

Immediate medical attention is necessary if an overdose is suspected or if signs of excessive fluid loss occur. Salurin treatment must be discontinued immediately in such cases. There is no specific antidote known for Furosemide overdose. Management is supportive, focusing on the replacement of excessive fluid and electrolyte losses. Frequent monitoring of serum electrolytes, carbon dioxide levels, and blood pressure is required to guide supportive care, necessitating a hospital setting.

Therapeutic Uses of Salurin

Quick Facts: Salurin

  • Primary Use: Management of the signs and symptoms of certain adult rheumatoid arthritis.
  • Secondary Use: Providing a therapeutic option for adult patients with moderate-to-severe plaque psoriasis.
  • Key Action: Supports the management of chronic disease activity.

What Salurin Treats: Main Uses and Benefits

Salurin is a prescription medication indicated for the comprehensive management of specific chronic inflammatory conditions. It provides a therapeutic option for adult patients navigating the complexities of rheumatoid arthritis that has not responded adequately to other treatments. Its primary application in this area is to assist in reducing the signs and symptoms of the condition and support the management of disease activity.

Additionally, Salurin is used to address moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In this context, it may help manage the extent and severity of skin plaques. The prescribing physician will determine if Salurin should be incorporated as part of a patient's overall treatment regimen, taking into account the individual's clinical picture and health objectives.

Eligibility and Restrictions for Use

Who can and cannot use Salurin?

The population eligibility for Salurin (Furosemide) is determined by official government regulatory documents, which establish clear restrictions based on patient status, organ function, and age.

Absolute Contraindications

Salurin must not be used by individuals with anuria (the inability to produce urine) or a known history of hypersensitivity to Furosemide or sulfonamide-derived drugs. Use is also prohibited in patients with severe, uncorrected hypovolemia (low blood volume) or dehydration, and in those in a state of hepatic coma or pre-coma.

Eligibility Limitations and Restrictions

Population Group Regulatory Status and Limitation
Pregnancy Not recommended unless the potential benefit justifies the risk; requires monitoring.
Lactation Contraindicated or Not recommended; may reduce breast milk production.
Neonates Restricted use due to the risk of nephrocalcinosis and nephrolithiasis (kidney risks).
Older Adults Requires caution and typically lower initial doses due to a higher risk of dehydration and electrolyte imbalance.
Hepatic/Renal Impairment Use is conditional in severe renal disease and requires strict observation in hepatic cirrhosis due to risk of encephalopathy.
Comorbidities Caution is required in patients with gout or diabetes mellitus due to the risk of hyperuricemia and altered glucose tolerance.

What should I know about interactions with other medicines?

Salurin (Furosemide) has documented interactions with other medicines and products that may affect exposure or enhance toxic effects, as described in official regulatory information.

Contraindicated Combinations and Enhanced Toxicity

Specific combinations are addressed with cautions or restrictions due to the risk of severe toxicity:

  • Ototoxic Agents: Co-administration with Ethacrynic acid is generally avoided due to the possibility of severe ototoxicity. Use with Aminoglycoside antibiotics should be avoided except in life-threatening situations due to increased ototoxic potential, especially with impaired renal function.
  • Lithium: Furosemide reduces the renal clearance of Lithium, leading to a high risk of Lithium toxicity. This combination is typically avoided.
  • Nephrotoxic Agents: The risk of nephrotoxicity and ototoxicity is increased with agents such as Cisplatin.

Pharmacodynamic and Exposure Interactions

  • Hypotension Risk: Concurrent use with other antihypertensive agents, including ACE Inhibitors and ARBs, may cause severe hypotension and deterioration of renal function.
  • Reduced Furosemide Effect: The simultaneous administration of oral Furosemide and Sucralfate may reduce Furosemide's effectiveness. The official labeling specifies that intake of these two substances must be separated by at least two hours.
  • Clearance Competition: High-dose Salicylates may result in salicylate toxicity at lower doses due to competition for renal excretory sites.
  • Population Note: In patients with hypoproteinemia, the Furosemide effect may be weakened, and the risk of ototoxicity is potentiated.

Mechanism of Action

Molecular Blockade of the Renal Salt Transporter ( NKCC2)

Salurin's primary action is the direct inhibition of the Na^+– K^+–2 Cl^- Cotransporter ( NKCC2), a high-capacity protein located on the epithelial cells of the kidney's thick ascending limb. The active ingredient, Furosemide, must first be actively transported into the tubular fluid via Organic Anion Transporters ( OATs) to reach this specific target site. This molecular blockade immediately prevents the reabsorption of a massive portion of filtered salt and water, which determines the drug's maximum mechanistic capacity and speed of action.

Mechanistic Cascade: Natriuresis and Systemic Fluid Volume Reduction

The inhibition of NKCC2 initiates a physiological cascade where the resulting concentration of unreabsorbed salt creates a strong osmotic force, retaining water within the renal tubule and leading to a pronounced and rapid increase in the excretion of salt and water (natriuresis and diuresis). This profound fluid shift results in a net reduction in the body's circulating plasma and interstitial fluid volume. The mechanism is dependent on high-capacity transport but can be physiologically constrained in states of reduced kidney perfusion, which impairs the delivery of the molecule to its site of action.

Dosage and Administration Information

How to Use Salurin: Official Administration Guidelines

Salurin (Furosemide) is administered according to prescribed routes, specific dosage regimens, and time-dependent schedules defined in its official labeling.

Instruction Official Administration Principle
Routes and Forms Administration is through oral forms (tablet or solution) or parenterally via intravenous (IV) or intramuscular (IM) injection. The parenteral route is typically reserved for acute situations or when oral intake is unfeasible.
Standard Oral Dosing The usual initial oral dose for adults is 20 mg to 80 mg as a single dose. Doses are adjusted gradually in 20 mg to 40 mg increments, with at least 6 to 8 hours between adjustments. The official maximum daily dose for severe edematous states generally does not exceed 600 mg.
Dosing Frequency The medicine is generally taken once daily for maintenance therapy. Alternative usage patterns include an intermittent schedule, such as administration on 2 to 4 consecutive days per week.
IV Administration Intravenous doses must be administered slowly over 1 to 2 minutes. The infusion rate is constrained and must not exceed 4 mg per minute to maintain proper procedural use. Conversion to the oral form is required as soon as clinically practical.
Specific Populations Older adults typically require a lower initial oral dose, commonly starting at 20 mg, with subsequent increases performed slowly. For patients with hepatic impairment, therapy initiation should occur in a monitored setting.

These official guidelines establish a standardized framework for the correct delivery of the drug, specifying precise starting amounts and strict time intervals for dose titration. The structure ensures adherence to the protocol by defining the appropriate administration route, dose progression, and required procedural constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Salurin (Furosemide)

Evidence for Use in Managing Fluid Retention in Heart Failure

The research examining Salurin (Furosemide) for managing fluid retention, or edema, associated with congestive heart failure includes multiple types of studies, such as Randomized Controlled Trials (RCTs) and comparative studies. These investigations were used in research exploring how symptoms change over time and for contributing to the evidence base often cited in therapeutic guidelines. Findings describe patterns observed in the studies where administration was associated with a pronounced increase in measured urine output, consistent with the compound's pharmacological classification. What remains less characterized is the long-term durability of the diuretic response in chronic fluid control, a phenomenon sometimes referred to as 'diuretic resistance.'

Evidence for Managing Edema Related to Kidney and Liver Conditions

Salurin was also studied for its use in patients experiencing fluid retention linked to renal disease and liver cirrhosis (fluid accumulation known as ascites). Research has explored its use in conditions marked by functional limitations and physiological imbalance. In studies involving liver disease and ascites, Salurin was typically evaluated in combination with another type of diuretic. Data for certain groups remain insufficient, particularly regarding the long-term consequences of continuous use and the observed responses to high doses in individuals with advanced renal failure. Results apply only to the populations studied.

Research on Acute Volume Management (Pulmonary Edema)

Research exploring Salurin's role in the acute application for pulmonary edema—a rapid, severe fluid accumulation in the lungs—focused on episodes where symptoms become more noticeable and disruptive. Studies reported that administration was associated with a very rapid onset of action, especially when given intravenously. Comparative evidence is lacking for large, modern RCTs that definitively isolate the effect of Salurin from other emergency supportive treatments administered simultaneously. Therefore, the research provides substantial documentation of the immediate physiological effect, but data are less defined for longer-term acute outcomes.

Frequently Asked Questions (FAQ)

Common questions about Salurin (FAQ)

Q: What should I do if I miss a dose of Salurin?

Official patient information states that if a dose is missed, it should typically be taken as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose is usually skipped, and the regular schedule is continued. Taking two doses at once to compensate for a missed dose is generally not recommended in the product information.

Q: Can I drink alcohol while taking Salurin (Furosemide)?

Regulatory documents indicate that combining Salurin with alcohol may increase the risk of orthostatic hypotension—a sudden drop in blood pressure when moving from a sitting or lying position to standing. Because of this potential effect, it is important to consult a healthcare provider for personalized guidance on alcohol consumption while taking Salurin.

Q: How often should I have blood tests while on Salurin?

According to the official product information, regular monitoring of serum electrolytes (such as potassium and sodium) and kidney function indicators is advised while taking Salurin. These tests help ensure proper fluid and electrolyte balance. For individuals with diabetes, product information also indicates the advisability of monitoring blood and urine glucose.

How should Salurin be stored and disposed of?

Storage and Disposal Requirements for Salurin

Official regulatory documents define specific conditions for storing and disposing of Salurin (furosemide) to maintain stability and safety.

Storage Conditions

Product Form Temperature Constraint Protection Requirement
Tablets Store below 30 C Keep in the original carton, protected from light and out of sight and reach of children.
Injection Solution Store below 25 C Keep in the outer carton, protected from light. Do not refrigerate or freeze.

Stability and Handling

The injection is typically for single use only. Once an ampoule is opened, or if the solution is diluted, it should be used immediately. If dilution is necessary, specific chemical compatibility rules apply (avoid strong acid solutions, pH < 5.5).

Disposal

To protect the environment, unused medicine and waste materials must not be disposed of via household waste or flushed down wastewater. Disposal must be carried out in accordance with local requirements, often by returning the medicine to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagOman

Equivalent of Salurin found in:

A-Z Index: